A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders

Inclusion Criteria: * Compliance with the NMOSD diagnostic criteria developed by the 2015 International NMO Diagnostic Team (IPND); * 18-65 years old , male or female; * At least 2 relapses occurred within 2 years before screening, or at least 1 relapse within 1 year before screening; * Discontinue the immunosuppressive agents such as azathioprine within 28 days before the baseline; * EDSS score ≤ 6; * Men and women with fertility must agree to use effective methods of contraception during treatment and within 12 months of treatment completion; * Agree to participate in the trial and sign the informed consent in writing. Exclusion Criteria: * Any monoclonal antibody treatment was used within 6 months prior to dosing; * Having been treated with anti-CD20 monoclonal antibody; * Live vaccine received within 4 weeks before screening; * Having participated in another clinical study within 1 month or 5 half-lives of the drug prior to the baseline (whichever is longer); * A history of allergies to monoclonal antibodies; severe allergic reaction to certain foods or drugs; * Abnormal liver function, kidney function and bone marrow reserve; * HIV-positive history or HIV-positive at screening; hepatitis B and/or hepatitis C history or hepatitis B surface antigen-positive at screening; or hepatitis C virus (HCV) antibody positive; treponema pallidum antibody positive when enrolled; * History of infections that investigators have identified as unsuitable for testing; * Patients with a clear history of heart disease ; * Have a history of mental disorders; * Pregnant or lactating women, and female subjects who have a positive pregnancy test at screening; * None of the investigators or their relatives participating in the study could be enrolled.